Did you know that spending 20 minutes in a hot sauna three times a week can be a highly effective treatment for depression?  Randomized clinical trials have dem ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Not everyone is having a Dry January. But on the heels — and buzzkill — of the surgeon general’s January 3 advisory warning ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

Swollen tongue might signal deeper health concerns. Find out how it could be a warning sign for conditions like nutritional ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of ...

An international committee of scientists has proposed changing the way obesity is defined and diagnosed. The proposal adds ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

People with lupus-related skin problems are more likely to develop heart disease associated with hardening of the a ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.